Content about Endo Pharmaceuticals

January 4, 2011
Endo's Fortesta receives FDA approval

The Food and Drug Administration has approved a topical testosterone replacement therapy made by Endo Pharmaceuticals, Endo said last week.

CHADDS FORD, Pa. — The Food and Drug Administration has approved a topical testosterone replacement therapy made by Endo Pharmaceuticals, Endo said last week.

The drug maker announced on Dec. 29 the approval of Fortesta (testosterone) gel, a treatment for men with low testosterone, which affects nearly 14 million men in the United States.

Endo said it planned to introduce Fortesta in the United States early this year.

December 1, 2010
Endo completes Qualitest acquisition

Endo Pharmaceuticals has finished its acquisition of Qualitest Pharmaceuticals for $1.2 billion, Endo said Wednesday.

CHADDS FORD, Pa. — Endo Pharmaceuticals has finished its acquisition of Qualitest Pharmaceuticals for $1.2 billion, Endo said Wednesday.

Endo had agreed to buy Qualitest, a privately owned manufacturer of generic drugs, on Dec. 28.

October 6, 2010
Watson, Endo settle Opana ER patent suit

Watson Pharmaceuticals has settled a patent lawsuit with Endo Pharmaceuticals concerning an Endo prescription painkiller,...

MORRISTOWN, N.J. Watson Pharmaceuticals has settled a patent lawsuit with Endo Pharmaceuticals concerning an Endo prescription painkiller, Watson said Thursday.

 

The generic drug maker said its subsidiary, Watson Labs, had received a royalty-free license to Endo’s patents covering the extended-release painkiller Opana ER (oxymorphone).

 

 

Watson will have the right to launch its version of the drug in September 2012. Other details of the settlement were not disclosed, Watson said.

 

September 27, 2010
Endo boosts portfolio with Qualitest acquisition

Endo Pharmaceuticals will acquire generic drug maker Qualitest Pharmaceuticals for $1.2 billion, Endo said Tuesday....

CHADDS FORD, Pa. Endo Pharmaceuticals will acquire generic drug maker Qualitest Pharmaceuticals for $1.2 billion, Endo said Tuesday.

Endo said the purchase of privately owned Qualitest would expand its offering of branded drugs, generics, devices and services in areas such as pain and urology. Qualitest is the sixth largest generic drug company in the United States, as measured by prescriptions filled.

September 21, 2010
FDA grants priority review for crush-resistant, long-acting oxymorphone

The Food and Drug Administration has granted priority review to an opioid painkiller designed to...

CHADDS FORD, Pa. The Food and Drug Administration has granted priority review to an opioid painkiller designed to thwart drug abusers.

 

Endo Pharmaceuticals said Wednesday that the FDA would expedite review of its new oral formulation of long-acting oxymorphone, which is designed to be crush-resistant. The FDA expects to take action on the drug in early January.

 

 

July 14, 2010
Endo completes HealthTronics acquisition

Endo Pharmaceuticals has completed its acquisition of a company that provides urological products and services,...

June 30, 2010
Endo resubmits application for approval for Fortesta

Endo Pharmaceuticals has resubmitted its application to the Food and Drug Administration for a testosterone...

June 7, 2010
Endo, Penwest grant Opana ER license to Impax

Endo Pharmaceuticals and Penwest Pharmaceuticals will grant Impax Labs a special license to sell a...

March 11, 2010
Endo names Julie McHugh COO

Endo Pharmaceuticals has appointed a new COO, the drug maker announced Friday....

January 18, 2010
Watson files application for Lidoderm generic

Watson Pharmaceuticals has filed for regulatory approval of a generic version of a pain drug...